Overview


According to FutureWise analysis, the market for Activated Partial Thromboplastin Test is expected to reach US$ 600 million by 2031 at a CAGR of 7.02% over the forecast period of 2023-2031.

A laboratory blood test called the Activated Partial Thromboplastin Test (APTT) measures the duration it takes for blood to clot. It assesses how well the blood's intrinsic coagulation pathway works, which involves several clotting factors. The primary purposes of the APTT test are to evaluate and keep track of deficits or abnormalities in clotting factors. Diagnosing and treating conditions like hemophilia, von Willebrand disease, lupus anticoagulant, and other inherited or acquired clotting problems is frequently prescribed. Several bleeding or clotting diseases can be diagnosed or monitored with the APTT test. It aids in tracking the efficacy of anticoagulant therapy (such as heparin), looking into the origins of unexplained bleeding or bruises, and determining the likelihood of excessive bleeding during operations or other invasive procedures. 

An activator, usually a negatively charged surface or a combination of phospholipids, and a contact activator, like kaolin or celite, are combined with the blood. To assess whether the clotting time is within normal bounds or whether there is a clotting problem, the length of time it takes for a clot to form is measured, and the findings are compared to a reference range. As part of their diagnostic or monitoring services, laboratories, hospitals, and other healthcare facilities that provide APTT testing are the end users in this market.

FutureWise Market Research has published a report that provides an insightful analysis of Activated Partial Thromboplastin Test Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, Activated Partial Thromboplastin Test Market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  •  Horiba International
  •  Bio-Rad Laboratories
  •  Takara Bio
  •  Thermo Fisher
  •  Johnson and Johnson
  •  Siemens Medical Solutions
  •  Abbott Laboratories
  •  BioMeriux, Inc.
  •  Eiken Chemical
  •  Life Technologies
  •  Beckman Coulter, Inc.
  •  Danaher Corporation
  •  Ortho-Clinical Diagnostics Corporation
  •  Becton, Dickinson and Company
  •  Roche Diagnostics

(Note: The list of the major players will be updated with the latest market scenario and trends)

Coagulation disorders, such as hemophilia, von Willebrand disease, and lupus anticoagulants, are becoming more prevalent globally. These disorders' rising incidence and prevalence drive the demand for diagnostic tests like APTT to diagnose and monitor patients accurately, contributing to market growth. Technological advancements in laboratory testing and automation have improved the accuracy, speed, and efficiency of APTT testing. The development of automated coagulation analyzers and point-of-care testing devices has made APTT testing more accessible and convenient. These advancements attract healthcare providers and laboratories to invest in APTT testing equipment, boosting market growth. The demand for point-of-care testing is increasing as it provides prompt and convenient test outcomes for patients in both hospital and non-hospital settings. Point-of-care APTT testing devices offer quick turnaround time and facilitate immediate decision-making, particularly in emergency and critical care settings. The convenience and efficiency of point-of-care testing drive the market demand. Favourable reimbursement policies and insurance coverage for APTT testing encourage healthcare providers to perform these tests. Reimbursement support reduces the financial burden on patients and increases the accessibility of APTT testing, contributing to market growth. However, The APTT market is subject to regulatory oversight, and compliance with regulatory requirements can pose challenges for manufacturers and suppliers. Strict product quality, safety, and performance regulations may result in lengthy approval processes and increased costs for bringing new APTT testing products to market. While APTT testing is a widely used coagulation test, alternative tests are available for assessing clotting function, such as the Prothrombin Time (PT) test and specific factor assays. Furthermore, depending on the particular clinical scenario, healthcare providers may choose alternative tests or a combination of tests, which can affect the demand for APTT testing, thereby limiting the market growth.

By Product Type

  •  Instruments
  •  Consumables

By Application

  •  Heparin therapy Monitoring
  •  Coagulation Factor Deficiencies Screening
  •  Coagulation Inhibitors

By Technology

  •  Optical Technology
  •  Mechanical Technology
  •  Electrochemical Technology

By End User

  •  Hospitals
  •  Clinics
  •  Laboratories
  •  Point- of care- testing

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

This market research report also emphasizes on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. North America has a high prevalence of cardiovascular diseases, such as heart attack and stroke. These diseases are often associated with abnormal blood clotting, which can be diagnosed and monitored using APTT tests. North America has a well-developed healthcare infrastructure, which includes a large number of hospitals and diagnostic laboratories. This infrastructure provides a strong base for the growth of the APTT test market, contributing to its dominance in the market.

  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the Activated Partial Thromboplastin Test Market By Product Type, By Application, By Technology, By End User and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Activated Partial Thromboplastin Test Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Activated Partial Thromboplastin Test Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Activated Partial Thromboplastin Test Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Activated Partial Thromboplastin Test Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Instruments
        2. Consumables

  • 8.   Global Activated Partial Thromboplastin Test Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Heparin therapy Monitoring
        2. Coagulation Factor Deficiencies Screening
        3. Coagulation Inhibitors

  • 9.   Global Activated Partial Thromboplastin Test Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Optical Technology
        2. Mechanical Technology
        3. Electrochemical Technology

  • 10.   Global Activated Partial Thromboplastin Test Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Laboratories
        4. Point- of care- testing

  • 11.   North America Activated Partial Thromboplastin Test Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Activated Partial Thromboplastin Test Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Activated Partial Thromboplastin Test Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Activated Partial Thromboplastin Test Market Analysis 2016-2020 and Forecast 2021-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2021-2028
  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Horiba International
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bio-Rad Laboratories
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Takara Bio
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Thermo Fisher
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Johnson and Johnson
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Siemens Medical Solutions
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Abbott Laboratories
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. BioMeriux, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Eiken Chemical
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
          10. Life Technologies
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Beckman Coulter, Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Danaher Corporation
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Ortho-Clinical Diagnostics Corporation
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
          14. Becton, Dickinson and Company
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
          15. Roche Diagnostics
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients